Bortezomib therapy has been proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM). However, both intrinsic and acquired resistance has already been observed. In this study, we explored the relationship between CD9 expression and bortezomib sensitivity in MM. We found that down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma. CD9 expression obviously increased bortezomib sensitivity through inducing apoptosis, significantly inhibiting U266 cells' adhesion to HS-5 and primary bone marrow stromal cells, but increasing U266 cells' adhesion to fibronectin. CD9 expression also significantly inhibited U266 cell migration. The mechanisms may include: the endoplasmic reticulum stress pathway, cell adhesion related signaling pathway and osteoclast differentiation related signaling pathway. Combination therapy with de-methylation reagent 5-Aza-2-deoxycytidine may prove useful to the development of novel strategies for the treatment of bortezomib-resistant MM patients.
References
[1]
Anderson KC (2004) Bortezomib therapy for myeloma. Curr Hematol Rep 3: 65.
[2]
Hemler ME (2005) Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6: 801–811. doi: 10.1038/nrm1736
[3]
Boucheix C, Rubinstein E (2001) Tetraspanins. Cell Mol Life Sci 58: 1189–1205. doi: 10.1007/pl00000933
[4]
Rubinstein E, Le Nour F, Lagaudriere-Gasbert C, Billard M, Conjeaud H, et al. (1996) CD9, CD63, CD61, CD81, and CD82 are components of a surface tetraspanin network connected to HLA-DR and VLA integrins. Eur J Immunol 26: 2657–2665. doi: 10.1002/eji.1830261117
[5]
Boucheix C, Soria C, Mirshahi M, Soria J, Perrot JY, et al. (1983) Characteristics of platelet aggregation induced by the monoclonal antibody ALB6 (acute lymphoblastic leukemia antigen p 24). Inhibition of aggregation by ALB6Fab. FEBS Lett 161: 289–295. doi: 10.1016/0014-5793(83)81027-8
[6]
Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R, et al. (1981) P-24: a human leukemia-associated and lymphohemopoietic progenitor cell surface structure identified with monoclonal antibody. J Exp Med 153: 726–731. doi: 10.1084/jem.153.3.726
[7]
Boucheix C, Benoit P, Frachet P, Billard M, Worthington RE, et al. (1991) Molecular cloning of the CD9 antigen. A new family of cell surface proteins. J Biol Chem 266: 117–122.
[8]
Lanza F, Wolf D, Fox CF, Kieffer N, Seyer JM, et al. (1991) cDNA cloning and expression of platelet p24/CD9. Evidence for a new family of multiple membrane-spanning proteins. J Biol Chem 266: 10638–10645.
[9]
Iwamoto R, Senoh H, Okada Y, Uchida T, Mekada E (1991) An antibody that inhibits the binding of diphtheria toxin to cells revealed the association of a 27-kDa membrane protein with the diphtheria toxin receptor. J Biol Chem 266: 20463–20469.
[10]
Mitamura T, Iwamoto R, Umata T, Yomo T, Urabe I, et al. The 27-kD diphtheria toxin receptor-associated protein (DRAP27) from vero cells is the monkey homologue of human CD9 antigen: expression of DRAP27 elevates the number of diphtheria toxin receptors on toxin-sensitive cells. J Cell Biol 118: 1389–1399. doi: 10.1083/jcb.118.6.1389
[11]
Fan J, Zhu GZ, Niles RM (2010) Expression and function of CD9 in melanoma cells. Mol Carcinog 49: 85–93. doi: 10.1002/mc.20580
[12]
Maecker HT, Todd SC, Levy S (1997) The tetraspanin superfamily: molecularfacilitators. FASEB J 11: 428–442.
[13]
Zoller M (2009) Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 9: 40–55. doi: 10.1038/nrc2543
[14]
Miyake M, Nakano K, Itoi SI, Koh T, Taki T (1996) Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 56: 1244–1249.
[15]
Higashiyama M, Doi O, Kodama K, Yokouchi H, Adachi M, et al. (1997) Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 74: 205–211. doi: 10.1002/(sici)1097-0215(19970422)74:2<205::aid-ijc12>3.0.co;2-c
[16]
Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, et al. (1998) Correlationof reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 153: 973–983. doi: 10.1016/s0002-9440(10)65639-8
[17]
Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, et al. (1998) Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 4: 1507–1510.
[18]
Hashida H, Takabayashi A, Tokuhara T, Hattori N, Taki T, et al. (2003) Clinical significance of transmembrane 4 superfamily in colon cancer. British Journal of Cancer 89: 158–167.
[19]
Sho M, Adachi M, Taki T, Hashida H, Konishi T, et al. (1998) Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 79: 509–516. doi: 10.1002/(sici)1097-0215(19981023)79:5<509::aid-ijc11>3.0.co;2-x
[20]
Buim ME, Louren？o SV, Carvalho KC, Cardim R, Pereira C, et al. (2010) Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. Oral Oncol 46: 166–171. doi: 10.1016/j.oraloncology.2009.11.009
[21]
Zheng R, Yano S, Zhang H, Nakataki E, Tachibana I, et al. (2005) CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncology Research 15: 365–372.
[22]
Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, et al. (2004) Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 23: 1326–1331. doi: 10.1038/sj.onc.1207313
[23]
Ying J, Li H, Seng TJ, Langford C, Srivastava G, et al. (2006) Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25: 1070–1080. doi: 10.1038/sj.onc.1209154
[24]
Won WJ, Kearney JF (2002) CD9 is a unique marker for marginal zone Bcells, B1 cells, and plasma cells in mice. J Immunol 168: 5605–5611. doi: 10.4049/jimmunol.168.11.5605
[25]
Barrena S, Almeida J, Yunta M, López A, Fernández-Mosteirín N, et al. (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 19: 1376–1383. doi: 10.1038/sj.leu.2403822
[26]
Wang HX, Li Q, Sharma C, Knoblich K, Hemler ME (2011) Tetraspanin protein contributions to cancer. Biochem Soc Trans 39: 547–552. doi: 10.1042/bst0390547
[27]
Richardson MM, Jennings LK, Zhang XA (2011) Tetraspanins and tumor progression. Clin Exp Metastasis 28: 261–270. doi: 10.1007/s10585-010-9365-5
[28]
De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, et al. (2008) Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 14: 2918–2926. doi: 10.1158/1078-0432.ccr-07-4489
[29]
Heller G, Schmidt WM, Ziegler B, Holzer S, Müllauer L, et al. (2008) Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 68: 44–54. doi: 10.1158/0008-5472.can-07-2531
[30]
Drucker L, Tohami T, Tartakover-Matalon S, Zismanov V, Shapiro H, et al. (2006) Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 27: 197–204. doi: 10.1093/carcin/bgi209
[31]
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585–598. doi: 10.1038/nrc2189
[32]
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658–1667.
[33]
Nefedova Y, Landowski TH, Dalton WS (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17: 1175–1182. doi: 10.1038/sj.leu.2402924
[34]
Neri P, Bahlis NJ (2012) Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets 12: 776–796. doi: 10.2174/156800912802429337
[35]
Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, et al. (2006) Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res 12: 591–599. doi: 10.1158/1078-0432.ccr-05-1792
[36]
Hazlehurst LA, Dalton WS (2001) Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 20: 43–50.
[37]
Li ZW, Dalton WS (2006) Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 20: 333–342. doi: 10.1016/j.blre.2005.08.003
[38]
Mujtaba T, Dou QP (2011) Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 12: 471–480.
[39]
Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL, Ron D. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev. 1998 Apr 1 12(7): 982–95. doi: 10.1101/gad.12.7.982
[40]
Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H (2005) TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death. EMBO J 24: 1243–1255. doi: 10.1038/sj.emboj.7600596
[41]
Pelletier AJ, Kunicki T, Ruggeri ZM, Quaranta V (1995) The activation state of the integrin alpha IIb beta 3 affects outside-in signals leading to cell spreading and focal adhesion kinase phosphorylation. J Biol Chem 270: 18133–18140. doi: 10.1074/jbc.270.30.18133
[42]
Nagaharu K, Zhang X, Yoshida T, Katoh D, Hanamura N, et al. (2011) Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 178: 754–763. doi: 10.1016/j.ajpath.2010.10.015
[43]
Su B, Gao L, Meng F, Guo LW, Rothschild J, et al. (2013) Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. Oncogene 32: 2016–2026. doi: 10.1038/onc.2012.218
